Skip to main content
Log in

Recent advances in the treatment of congestive heart failure

  • Symposium: Pediatric Cardiology — Part I
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Treatment of heart failure should include correction of the underlying cause. These causes include large left to right shunts, obstructive lesions, arrhythmias, primary myocardial disease etc. The main pharmacological therapy includes inotropic agents, vasodilators and diuretics. Inotropic agents increase myocardial contractility and include digoxin, intravenous dopamine, dobutamine and isoproterenol. Vasodilators improve cardiac pump performance by decreasing the vascular resistance and/or increasing the venous capacitance. Commonly used vasodilator agents include angiotensin converting enzyme inhibitors (captopril, enalapril etc.), hydralazine, prazosin hydrochloride etc. Diuretics inhibit salt and water reabsorption promoting their excretion. Furosemide, thiazide diuretics, aldactone, are commonly used diuretics. Electrolyte and acid-base imbalance can occur on chronic diuretic therapy. Cardiac transplantation is considered for patients where all medical management has failed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Katz AM. Changing strategies in the management of heart failure.J Am Coll Cardiol, 1989; 13: 513–523.

    PubMed  CAS  Google Scholar 

  2. Parmely WW. Pathophysiology and current therapy of congestive heart failure.J Am Coll Cardiol, 1989; 13: 771–785.

    Article  Google Scholar 

  3. Cohn JN. The management of chronic heart failure.N Engl J Med, 1996; 335: 490–498.

    Article  PubMed  CAS  Google Scholar 

  4. Heart Disease in Infants, Children and Adolsecents. 5th Edition, Baltimore: Williams and Wilkins, 1995. Talner NS,Heart Failure, 1746–1773, Emmanouilides GC, Riemenschneider TA, Allen HD, Gutgesell HP (eds).

    Google Scholar 

  5. The Science and Practice of Pediatric Cardiology, Philadelphia: Lea and Febiger, 1990. Dreyer WJ, Congestive Heart Failure, 2007–2023. Garson Jr. A, Bricker, JT, McNamara DG (eds).

    Google Scholar 

  6. Artman M, Parrish MD, Graham TP Jr. Congestive heart failure in childhood and adolescence: recognition and management.Am Heart J 1983; 105: 471–480.

    Article  PubMed  CAS  Google Scholar 

  7. Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children.Am Heart J, 1987; 113: 994–1005.

    Article  PubMed  CAS  Google Scholar 

  8. Parmley WW. Neuroendocrine changes in heart failure and their clinical relevance.Clin Cardiol 1995; 18: 440–445.

    Article  PubMed  CAS  Google Scholar 

  9. Opie LH. Fundamental role of angiotensin converting enzyme inhibitors in the management of congestive heart failure.Am J Cardiol 1995; 75: 3F-6F.

    Article  PubMed  CAS  Google Scholar 

  10. Waagstein F, Bristow MR, Swedberg K,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Lancet 1993; 342: 1441–1446.

    Article  PubMed  CAS  Google Scholar 

  11. Packer M, Bristow MR, Cohn JN,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.N Engl J Med 1996; 334: 1349–1355.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Sc. Recent advances in the treatment of congestive heart failure. Indian J Pediatr 65, 13–20 (1998). https://doi.org/10.1007/BF02849687

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02849687

Key words

Navigation